GSTM1 and type 2 diabetes mellitus: This experimental finding is consistent with the findings of increased systemic EPO levels and hemoglobin concentration (Hb)/hematocrit, in type 2 diabetes mellitus patients treated with this class of medication (Mazer et al., 2020; Verma et al., 2019).